KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia-Reference-Cited by-同舟云学术

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia

Published:2013-02-04 Issue:1 Volume:161 Page:117-127
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Etchin Julia,Sanda Takaomi,Mansour Marc R.,Kentsis Alex,Montero Joan,Le Bonnie T.,Christie Amanda L.,McCauley Dilara¹,Rodig Scott J.,Kauffman Michael¹,Shacham Sharon¹,Stone Richard,Letai Anthony,Kung Andrew L.,Thomas Look A.

Affiliation:

1. Karyopharm Therapeutics; Natick; MA; USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12231/fullpdf

Reference42 articles.

1. Molecular genetics of acute lymphoblastic leukemia;Armstrong;Journal of Clinical Oncology,2005

2. Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport;Bonazzi;Journal of the American Chemical Society,2010

3. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export;Daelemans;Proceedings of the National Academy of Sciences of the United States of America,2002